



December 15, 2011

Voluntary US Market Discontinuation of Amevive® (alefacept)

Dear Doctor,

Astellas Pharma US, Inc. would like to inform you of its decision to cease promotion, manufacturing, distribution and sales of Amevive. The decision to discontinue Amevive was driven by business needs. As you may or may not be aware, Amevive is currently experiencing a supply disruption, however this event is not the basis for discontinuation.

Additionally, the decision to cease Amevive sales is neither the result of any specific safety concern nor the result of FDA-mandated or voluntary product recall.

Astellas recommends physicians not initiate Amevive for new patients. If initiating therapy or if a patient is currently receiving Amevive, Astellas recommends checking with your dispensing pharmacy for availability of Amevive. If unable to secure supply to complete a current or planned course of therapy please transition patients immediately to alternate therapies as appropriate. For current patients, Astellas will maintain current Amevive support programs (e.g. Astellas reimbursement services, Patient Assistance Program) through March 16, 2012.

After Amevive discontinuation prescribers should continue to monitor patients as usual.

Please see subsequent page for additional details. Should you have any clinical or medical questions regarding the use of Amevive please call the Astellas Medical Information Department at 1-800-727-7003. For all other questions about Amevive, contact Customer Services at 1-800-888-7704.

Sincerely,

Walt Johnston
Vice President, Marketing
Astellas Pharma US, Inc.

Astellas Pharma US, Inc.

Three Parkway North, Deerfield, IL 60015-2537
Tel: 1-800-888-7704 Fax: 1-800-688-6668

011K-040-4566-22 12/11



Guidance for Prescribers:

- Astellas ceased distribution of Amevive (alefacept) to wholesalers and distributors on November 16, 2011
- Prescribers should not initiate Amevive treatment for any new patients
- Prescribers should check with dispensing pharmacies for availability of Amevive before initiating current or planned courses of therapy
- Prescribers should carefully manage the transition of patients from Amevive to other appropriate therapies
- After Amevive discontinuation, prescribers should continue to monitor patients as usual
- Adverse events should be reported to Astellas at 1-800-727-7003 or FDA at www.fda.gov/medwatch or 1-800-FDA-1088

Returns Process:

- Return all Amevive inventory to the Astellas return goods vendor (GENCO) from January 16, 2012 through November 16, 2012 for either (i) the full contract price if you purchased the product under an Astellas pricing agreement or (ii) 100% of current WAC if your purchase was not made under an Astellas pricing agreement

GENCO Pharmaceutical Services

Astellas Pharma US, Inc. Returns
6101 N. 64th St.
Milwaukee, WI 53218
1-800-950-5479

- No returns will be accepted after November 16, 2012
- Please complete the appropriate return goods form(s) and follow all appropriate instructions

Astellas Pharma US, Inc.

Three Parkway North, Deerfield, IL 60015-2537
Tel: 1-800-888-7704 Fax: 1-800-688-6668

011K-040-4566-22 12/11